It is noteworthy that the anti-EGFR antibody Cetuximab was evaluated in a pilot study as a single agent in patients with refractory or relapsed MM who had previously received at least one line of prior treatment and were not eligible to undergo autologous stem cell transplantation [69]. This evidence concerns the gene EGFR and Miyoshi myopathy.